The influence of circumferential resection margin status on Loco-regional recurrence in esophageal squamous cell carcinoma
Article first published online: 31 DEC 2012
Copyright © 2012 Wiley Periodicals, Inc.
Journal of Surgical Oncology
Volume 107, Issue 7, pages 762–766, 1 June 2013
How to Cite
Park, H. J., Kim, H. J., Chie, E. K., Kang, C. H. and Kim, Y. T. (2013), The influence of circumferential resection margin status on Loco-regional recurrence in esophageal squamous cell carcinoma. J. Surg. Oncol., 107: 762–766. doi: 10.1002/jso.23313
- Issue published online: 25 MAY 2013
- Article first published online: 31 DEC 2012
- Manuscript Accepted: 6 DEC 2012
- Manuscript Received: 28 OCT 2012
- circumferential resection margin;
- esophageal squamous cell carcinoma;
To analyze treatment outcomes and patterns of recurrence, and to examine the impact of adjuvant postoperative radiotherapy (PORT) after esophagectomy in esophageal squamous cell carcinoma (SqCC) regarding the status of circumferential resection margin (CRM).
Patients and Methods
We performed a retrospective review of esophageal cancer patients operated in Seoul National University Hospital between 2003 and 2010. Pathologically proven T3 SqCC patients with written reports mentioning the status of CRM were selected. Fifty-nine out of 71 patients (83.1%) had CRM+. Twenty-eight patients had radiotherapy in CRM+ and CRM−, respectively. The median follow-up period was 17.1 months (range: 5.2–63.1).
Median survival and 2-year overall survival were 13.8 months and 41.9% in CRM+, and 27.3 months and 74.1% in CRM−, respectively. Loco-regional relapse-free survival (LRRFS) rate at 2 years was 33.6% and 74.1% in each groups (P = 0.029). Loco-regional recurrence was the major pattern of failure in CRM+. PORT did not improve LRRFS.
The esophageal SqCC patients with CRM+ after resection showed worse LRRFS. This finding validated the prognostic value of CRM status. Nevertheless, we failed to demonstrate the benefits of adjuvant PORT in CRM+. This might suggest the necessity of neoadjuvant therapy to decrease the CRM+ rate after esophagectomy. J. Surg. Oncol. 2013;107:762–766. © 2012 Wiley Periodicals, Inc.